Cancer - E4412: Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Condition or Therapy:
Relapsed or Refractory Hodgkin Lymphoma
What is the goal of this study?
The goal of this study is to answer the following question: Does adding ipilimumab to brentuximab vedotin and nivolumab extend a patient's time without disease?
Researchers will also compare any side effects patients may have when they take the study drugs and for up to 10 years after they stop taking these drugs.
Who can join the study?
This study may be a good fit for children who:
- Are 12 years of age or older
- Have newly diagnosed relapsed or refractory Hodgkin Lymphoma
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for your child.
What will happen if my child takes part in this study?
Participants in this study will be asked to:
- Come in weekly during the first course of treatment
- Come in once per cycle for all subsequent courses of treatment
- Keep us updated with your health and any side effects you may experience
Who can I contact for more information?
Please email the research coordinator or call the study team at (206) 987-2106 for more information about this study.